Press "Enter" to skip to content

NuView Life Sciences Secures $90 Million Capital Commitment

This content may contain forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995 or by the SEC in its rules, regulations, and releases.

Clinical stage oncology firm NuView Life Sciences announces a $90 million agreement with international investment group GEM Global Yield for the purpose of developing a promising Theranostic.

NuView Life Sciences, Inc. announced that it has signed an agreement with GEM Global Yield LLC SCS, a Luxembourg-based private, alternative investment group.

Under the accord, GEM agrees to purchase common shares from NuView on a firm commitment basis with an aggregate value of USD$90 million, upon NuView filing a Registration Statement with the U.S. Securities and Exchange Commission (SEC). The agreement provides NuView a 36-month drawdown period.

NuView will use funds to complete a 600-patient in vitro double-blind clinical trial in accordance with the U.S. Food and Drug Administration (FDA) approval process. NuView will also allocate funds for its in vivo diagnostics and Theranostic programs. 

NuView controls the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation.

The NV-VPAC1 test has been successfully utilized for in vitro and in vivo diagnostics detecting multiple types of cancer. In clinical studies, the test showed its ability to accurately detect cancer cells and their location not only inside the body, but outside as well, in voided biofluids, confirming the presence of shed cancer cells.

NuView is confident the test has the potential for diagnosing a variety of cancers, transforming patient care. The GEM endorsement greatly expedites the process towards potential commercialization.

“This agreement with GEM helps to secure the funding for continued growth and development of NuView’s NV-VPAC1Ô portfolio. As we focus on moving our in vitro cancer diagnostics into the marketplace, we can simultaneously restart our in vivo diagnostics and Theranostic programs forward,” stated Paul Crowe, Chairman and CEO of NuView.

Global Emerging Markets is a $3.4 billion, alternative investment group with operations in Paris, New York, and Los Angeles.

GEM manages a diverse set of investment vehicles focused on emerging markets that provide the group and its investors with a diversified portfolio of asset classes that span the global private investing spectrum.

Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile.

The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments.

NuView Life Sciences, located in Park City, UT, is an innovative, clinical stage, precision oncology company. NuView’s mission is to change the way cancer is currently diagnosed and treated.

The earlier cancer is identified, the better the treatment options are and the greater the chances for successful outcomes.

Be First to Comment

Leave a Reply

%d bloggers like this:
Close Bitnami banner